Cooling Off Hot Hearts: A Specific Therapy for Vulnerable Plaque?⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.  by Vogel, Robert A. & Forrester, James S.
c
p
s
i
t
n
A
t
c
p
s
c
o
a
r
u
a
s
W
p
e
f
s
w
p
r
A
U
I
r
Journal of the American College of Cardiology Vol. 61, No. 4, 2013
© 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.10.026EDITORIAL COMMENT
Cooling Off Hot Hearts:
A Specific Therapy
for Vulnerable Plaque?*
Robert A. Vogel, MD,† James S. Forrester, MD‡
Denver, Colorado; and Los Angeles, California
A few decades ago, cardiac pathologists taught us that
coronary atheroma can be either stable or vulnerable. The
vulnerable plaque has the key histological features of local
inflammation: a higher temperature, roughly 4 times more
macrophages than stable plaques, and a thin fibrous cap only
one-third as thick as stable atheroma (1–4). Because acute
oronary syndromes (ACS) are caused by vulnerable
laques, therapy targeting the inflammatory process has
eemed compellingly rational.
See page 404
The early logical choice among anti-inflammatory ther-
apies was corticosteroids. A 2002 meta-analysis of 11 trials
(2,646 patients) revealed a 26% decrease in mortality with
corticosteroids in acute myocardial infarction (AMI) (odds
ratio: 0.74; 95% confidence interval [CI]: 0.59 to 0.94), but
sensitivity analysis limited to randomized, controlled trials
showed lack of efficacy (odds ratio: 0.95; 95% CI: 0.72 to
1.26) (5). Steroids were abandoned amidst concern for
mpaired wall healing resulting in cardiac rupture, although
his risk may be lessened with concomitant reperfusion (6).
In subsequent years, attention focused on selective and
onselective nonsteroidal anti-inflammatory drugs (NSAIDs).
ll of these agents, with the exception of aspirin, increase
he risk for AMI, especially in those patients known to have
oronary heart disease. A recent Danish study of 99,187
atients experiencing a first-time AMI reported that sub-
equent NSAID use was persistently associated with in-
reased mortality (hazard ratio: 1.63; 95% CI: 1.52 to 1.74)
ver a 5-year period (7).
Still, provocative hints remained. The well-documented
nti-inflammatory effects of statins may play a role in
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sed in noncardiac conditions, such as methotrexate in
rthritis and psoriasis, seem to reduce cardiac events. One
uch intriguing anti-inflammatory candidate is colchicine.
ith its array of anti-inflammatory actions on macro-
hages, neutrophils, and endothelial cells, it is highly
ffective in management in gout, recurrent pericarditis, and
amiliar Mediterranean fever (8). In a retrospective, cross-
ectional study of 1,288 patients with gout, colchicine use
as associated with a lower incidence of MI (1.2% vs. 2.6%;
 0.03) than nonuse (9). There were also fewer deaths
and lower C-reactive protein (CRP) levels in colchicine
users than nonusers in this study, although CRP levels did
not decrease in another study of patients with ACS or acute
ischemic stroke (10). Colchicine has not been found to
educe post-angioplasty restenosis (11).
In this issue of the Journal, Nidorf et al. (12) presented
the first trial of colchicine as an anti-inflammatory therapy
in coronary disease. In a prospective, randomized, observer-
blinded endpoint (PROBE) design study of 532 patients
with stable coronary artery disease receiving aspirin and/or
clopidogrel (93%) and statins (95%), patients were assigned
to colchicine 0.5 mg/day or no colchicine and followed for
a median of 3 years (12). The primary outcome was a
composite of ACS, out-of-hospital cardiac arrest, or non-
cardioembolic ischemic stroke. By intent-to-treat analysis,
this outcome occurred in 5% of the colchicine cohort
compared with 16% of patients assigned to no colchicine,
with a highly significant hazard ratio of 0.33. The well-
known narrow toxic/therapeutic ratio of colchicine was
responsible for 11% withdrawal of colchicine within 30
days, and another 11% withdrew from therapy later. Nev-
ertheless, on-treatment analysis produced analogous out-
comes, with a reduction in ACS (4.6% vs. 13.6%) as the
predominant reason for the difference.
The colchicine study carries the potential to be a break-
through for anti-inflammatory therapy in coronary artery
disease. The magnitude of the reported treatment effect is
striking, both in magnitude and in contrast to prior studies
of anti-inflammatory therapy. The 67% coronary event
reduction with colchicine is about twice that obtained with
aggressive statin therapy.
On the other hand, the study is best viewed as hypothesis
generating rather than a mandate for therapy for several
reasons. The reported efficacy may be too good to be true, a
familiar scenario for initial reports of therapies studied in
relatively small cohorts. But if even only partly true, larger
studies should have no difficulty demonstrating significance.
The 5.3% annual incidence of cardiovascular events in the
no colchicine group, especially considering the very frequent
use of statins and antiplatelet agents, is somewhat higher
than expected. By contrast, the COURAGE (Clinical
Outcomes Utilizing Revascularization and Aggressive Drug
Evaluation) trial reported an 11.8% incidence of ACS in the
optimal medical treatment cohort over 4.6 years, whereas
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Cooling Off Hot Hearts January 29, 2013:411–2the current study reported a 13.6% incidence of ACS in the
no colchicine group over 3 years (13). As the authors
acknowledged, the PROBE design is less rigorous than that
of a randomized clinical trial. Finally, the current study did
not provide information on the mechanism of colchicine’s
efficacy, leaving us ignorant of whether anti-inflammatory
effects should be predominantly local, systemic, or both and
which inflammatory processes to target. In this context,
Nidorf et al. (12) previously reported a 60% reduction in
RP levels with colchicine in patients with stable coronary
rtery disease and CRP levels 2.0 mg/l, but they did not
nd a decrease in CRP levels when colchicine was used in
he setting of ACS or acute ischemic stroke (11).
The colchicine trial now stands as a harbinger of several new
nti-inflammatory trials. Among these are the CANTOS
Canakinumab Anti-inflammatory Thrombosis Outcomes
tudy) and the CIRT (Cardiovascular Inflammation Re-
uction Trial) trials. The CANTOS trial will evaluate the
ffectiveness of a human monoclonal antibody to the in-
ammatory cytokine interleukin 1-beta in 17,200 stable
atients post-MI, randomized to subcutaneous drug or
lacebo and followed over 4 years (14). The CIRT study
ill determine the effect of low-dose methotrexate (10 to 20
g/week) on cardiovascular events in 7,000 patients with
rior AMI, elevated CRP levels, and type 2 diabetes (15).
While we await new trials, the striking additional reduction
n events in statin-treated patients on anti-inflammatory ther-
py already suggests a new concept: the lipid effects of
tatins may predominantly inhibit atherogenesis, whereas
pecific anti-inflammatory agents, such as colchicine, may
ork synergistically with statins to inhibit plaque rupture. If
he results can be confirmed, this study may one day stand
s the seminal trial in the use of anti-inflammatory therapy
o cool off hot hearts.
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